Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine (SGIM) Annual Meeting being held in Boston, MA.

Dr. Nancy Rigotti, ORCA-V1 Principal Investigator and Professor of Medicine at Harvard Medical School, and Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, will present data from the Phase 2 ORCA-V1 trial. This study explored the efficacy and safety of cytisinicline in adult smokers seeking to quit nicotine e-cigarettes. In the study, treatment with cytisinicline more than doubled the likelihood of quitting compared to placebo.

“We are honored to have the ORCA-V1 findings presented at the SGIM Annual Meeting as we believe this audience of healthcare providers plays a vital role in helping people who battle with nicotine dependence in its various forms,” stated Cindy Jacobs, MD, PhD, President and Chief Medical Officer at Achieve Life Sciences. “Cytisinicline has shown promising data in aiding smoking cessation, has been well tolerated, and we believe it will be key in helping people quit vaping as well.”

Dr. Rigotti’s presentation will be included in the “SAN2: Scientific Abstract Oral Presentations in Mental/Behavioral Health and Substance Use” session today, Friday, May 17, at 2:45 PM EDT.

The research and clinical study discussed in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health (NIH) under Award Number 4R44DA054784-02. The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.

About ORCA-V1
The Phase 2 ORCA-V1 trial evaluated 160 adults who used e-cigarettes on a daily basis at 5 clinical trial locations in the United States. ORCA-V1 participants were randomized to receive 3 mg cytisinicline three times daily or placebo for 12 weeks in combination with standard cessation behavioral support. The dose and administration of cytisinicline in the ORCA-V1 study is identical to that used in the Phase 3 registrational trials for smoking cessation. ORCA-V1 was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) through grant funding which was awarded in two phases totaling $2.8 million.